ChemicalBook Product Catalog Biochemical Engineering Biochemical Reagents Amino Acids H-D-Glu(Trp-OH)-OH

H-D-Glu(Trp-OH)-OH

Product NameH-D-Glu(Trp-OH)-OH
CAS229305-39-9
MFC16H19N3O5
MW333.34
EINECS
MOL File229305-39-9.mol

Chemical Properties

Boiling point	737.3±60.0 °C(Predicted)
Density	1.428±0.06 g/cm3(Predicted)
storage temp.	−20°C
solubility	Soluble in DMSO
pka	2.22±0.10(Predicted)
form	Solid
color	White to off-white

Safety Information

WGK Germany

MSDS

Provider	Language
SigmaAldrich	English

Usage And Synthesis

Uses

Golotimod (SCV-07), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod (SCV-07) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod (SCV-07) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2)[1][2][3].

Definition

ChEBI: Golotimod is a dipeptide.

in vivo

Golotimod (SCV-07) (oral gavage or subcutaneous injection, 100 μg/kg, 5 days) reduces experimental recurrent genital HSV-2 disease by oral administration, more importantly, oral SCV07 after fasting shows a greater reduction in incidence and severity than SCV-07 without fasting in female hartley guinea pigs^[1].
Golotimod (SCV-07) (subcutaneous injection, once or twice a day from days 1 to 20, 100 μg/kg) can reduce the severity and duration of acute and split radiation-induced oral mucositis (OM) and short the duration of ulcerative OM in male LVG golden Syrian Hamsters^[3].

Animal Model:	Female Hartley guinea pigs (250-300 g) infected HSV-2^[1]
Dosage:	100 μg/kg
Administration:	Oral gavage or subcutaneous injection; 5 days
Result:	Reduced incidence of lesions from 55% (one week before treatment) to only 18% by oral administration, and showed no significant reduction in disease by subcutaneous injection of SCV-07.

Animal Model:	Male LVG golden Syrian Hamsters weighing approximately 80 g with radiation-induced mucositis^[3]
Dosage:	10, 100 μg/kg or 1 mg/kg
Administration:	Subcutaneous injection; once or twice a day from days 1 to 20
Result:	Showed a peak mucositis of 3.0 on day 18 in the control group compared to only 2.2 in the test group, and the mucositis score in the SCV-07 treated hamsters was only 6.3% compared to 28.1% in the control group at dose of 100 μg/kg. Significantly decreased the severity and duration of oral mucositis (OM) at dose of 10 μg/kg, 100 μg/kg or 1 mg/kg.

IC 50

STAT3

References

[1] Rose WA 2nd, et al. An immunomodulating dipeptide, SCV-07, is a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2). Int J Antimicrob Agents. 2008 Sep;32(3):262-6. DOI:10.1016/j.ijantimicag.2008.04.010
[2] Geiger JL, et al. The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations. Oral Oncol. 2016 May;56:84-92. DOI:10.1016/j.oraloncology.2015.11.022
[3] Watkins B, et al. Attenuation of radiation- and chemoradiation-induced mucositis using gamma-D-glutamyl-L-tryptophan (SCV-07). Oral Dis. 2010 Oct;16(7):655-60. DOI:10.1111/j.1601-0825.2010.01671.x

H-D-Glu(Trp-OH)-OH Supplier

H-D-Glu(Trp-OH)-OH manufacturers

Related Product Information

Send Inquriy